公开(公告)号：US20240085438A1

公开(公告)日：2024-03-14

申请号：US18340235

申请日：2023-06-23

申请人： SPHingotec GMBH

发明人： Andreas BERGMANN

IPC分类号： G01N33/74

CPC分类号： G01N33/74 ,  G01N2800/26 ,  G01N2800/52

摘要： An in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay containing two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions contains at least 4 or 5 amino acids, and further assays and calibration methods.

公开(公告)号：US20210285949A1

公开(公告)日：2021-09-16

申请号：US17201518

申请日：2021-03-15

申请人： SphingoTec GmbH ,  AdrenoMed AG

发明人： Andreas BERGMANN

IPC分类号： G01N33/569 ,  G01N33/68 ,  C07K16/22 ,  A61P31/14

摘要： Subject matter of the present invention is a method for (a) diagnosing or predicting the risk of life-threatening deterioration or an adverse event or (b) prognosing the severity or (c) predicting or monitoring the success of a therapy or intervention in a patient infected with a Corona virus, the method comprising: determining the level of pro-Adrenomedullin (SEQ ID No. 31) or fragment thereof in a sample of bodily fluid of said patient, comparing said level of pro-Adrenomedullin or fragment thereof to a pre-determined threshold or a previous level of pro-Adrenomedullin or fragment thereof, and correlating said level of pro-Adrenomedullin or fragment thereof with the risk of life-threatening deterioration or an adverse event, or correlating said level of pro-Adrenomedullin or fragment thereof with the severity, or correlating said level of pro-Adrenomedullin or fragment thereof with the success of a therapy or intervention, wherein said pro-Adrenomedullin or fragment thereof is selected from the group consisting of PAMP (SEQ ID No. 32), MR-proADM (SEQ ID No. 33), ADM-NH2 (SEQ ID No. 20), ADM-Gly (SEQ ID No. 21) and CT-proADM (SEQ ID No. 34). Subject matter of the present invention is an Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy or intervention in a patient in a patient infected with a Corona virus.

公开(公告)号：US20210109102A1

公开(公告)日：2021-04-15

申请号：US17131008

申请日：2020-12-22

申请人： SPHINGOTEC GMBH

发明人： Andreas BERGMANN ,  Olle MELANDER

IPC分类号： G01N33/574 ,  G01N33/74

摘要： Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of pro-neurotensin or fragments thereof with the a risk for getting cancer, wherein an elevated level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an elevated level is correlated with the diagnosis of cancer and, wherein said cancer is selected from the group comprising breast cancer, lung cancer, pancreatic cancer and colon cancer.

公开(公告)号：US20170234889A1

公开(公告)日：2017-08-17

申请号：US15514663

申请日：2015-10-01

申请人： Sphingotec GmbH

发明人： Andreas BERGMANN ,  Olle MELANDER ,  Leong NG

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/72 ,  G01N2800/50 ,  G01N2800/52

摘要： A method of determining whether a subject has a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta-Adrenoreceptor Blocker (Beta-blocker) and/or statins) by determining the level of hGH, and/or its isoforms in a blood sample of said subject and comparing the determined level of hGH, and/or its isoforms in said blood sample with a pre-determined threshold.

公开(公告)号：US20210333292A1

公开(公告)日：2021-10-28

申请号：US17328100

申请日：2021-05-24

申请人： SPHINGOTEC GMBH

发明人： Andreas BERGMANN

IPC分类号： G01N33/74 ,  G01N33/68 ,  G01N33/543

摘要： A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.

公开(公告)号：US20200249246A1

公开(公告)日：2020-08-06

申请号：US16781226

申请日：2020-02-04

申请人： SphingoTec GmbH

发明人： Andreas BERGMANN

IPC分类号： G01N33/74 ,  C07K16/26 ,  G01N33/68

摘要： Subject matter of the present invention is an in vitro method for identifying a subject in need of administration of fluid resuscitation or a vasopressor comprising the following steps: Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject Correlating said level with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.

公开(公告)号：US20160097781A1

公开(公告)日：2016-04-07

申请号：US14872629

申请日：2015-10-01

申请人： SPHINGOTEC GMBH

发明人： Andreas BERGMANN ,  Olle MELANDER

IPC分类号： G01N33/74

CPC分类号： G01N33/74 ,  G01N33/6893 ,  G01N2800/362

摘要： Subject matter of the present invention is a method for stratifying a female subject for hormone replacement therapy wherein the level of Pro-Neurotensin or fragments thereof is determined and the level of Pro-Enkephalin or fragments thereof is determined.

摘要翻译： 本发明的主题是一种用于分级雌激素替代疗法的雌性受试者的方法，其中确定了神经降压素或其片段的水平，并测定了前脑啡肽或其片段的水平。

公开(公告)号：US20230147663A1

公开(公告)日：2023-05-11

申请号：US17955765

申请日：2022-09-29

申请人： SPHINGOTEC GMBH

发明人： Andreas BERGMANN ,  Olle Melander

IPC分类号： G01N33/574

CPC分类号： G01N33/57415 ,  G01N33/57423 ,  G01N2333/665 ,  G01N2800/50

摘要： Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising:

determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and
correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.

公开(公告)号：US20230127440A1

公开(公告)日：2023-04-27

申请号：US17986255

申请日：2022-11-14

申请人： Sphingotec GmbH

发明人： Andreas BERGMANN ,  Olle MELANDER

IPC分类号： G01N33/68 ,  G01N33/74

摘要： The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (CKD) using Pro-Enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases. Subject matter of the invention is also a method of predicting the worsening or improvement of kidney function or dysfunction in healthy and diseased individuals.

公开(公告)号：US20220291234A1

公开(公告)日：2022-09-15

申请号：US17635265

申请日：2020-08-14

申请人： SPHINGOTEC GMBH

发明人： Andreas BERGMANN ,  Saskia DE WILDT

IPC分类号： G01N33/68 ,  G16H50/20 ,  G16H50/30

摘要： (a) diagnosing or monitoring kidney function in a subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse event in a diseased subject, wherein said adverse event is selected from the group comprising worsening of kidney function including kidney failure, loss of kidney function and end-stage kidney disease or death due to kidney dysfunction including kidney failure, loss of kidney function and end-stage kidney disease or (d) predicting or monitoring the success of a therapy or intervention: determining the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with kidney function in a subject.